Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting...
Trimble, Cornelia L;Morrow, Matthew P;Kraynyak, Kimberly A;Shen, Xuefei;Dallas, Michael;Yan, Jian;Edwards, Lance;Lamar Parker, R;Denny, Lynette;Giffear, Mary;Shah Brown, Ami;Marcozzi-Pierce, Kathleen;Shah, Divya;Slager, Anna M;Sylvester, Albert J;Khan, Amir;Broderick, Kate E;Juba, Robert J;Herring, Timothy A;Boyer, Jean;Lee, Jessica;Sardesai, Niranjan Y;Weiner, David B;Bagarazzi, Mark L
2015-09-18 00:00:00
http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.pngThe LancetUnpaywallhttp://www.deepdyve.com/lp/unpaywall/safety-efficacy-and-immunogenicity-of-vgx-3100-a-therapeutic-synthetic-gQxkLPQnU4
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
